-
Mashup Score: 13The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors - 22 day(s) ago
Tipifarnib is the only targeted therapy breakthrough for HRAS-mutant (HRASmt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRASmt cancers are difficult to explore given the low frequency of HRASmt. This study aims to understand the molecular co-alterations, immune profiles, and clinical outcomes of 524 HRASmt solid tumors including urothelial carcinoma (UC), breast cancer (BC), non-small-cell lung cancer (NSCLC), melanoma, and HNSCC. HRASmt was most common in UC (3.0%), followed by HNSCC (2.82%), melanoma (1.05%), BC (0.45%), and NSCLC (0.44%). HRASmt was absent in Her2+ BC regardless of hormone receptor status. HRASmt was more frequently associated with squamous compared to non-squamous NSCLC (60% vs. 40% in HRASwt, p = 0.002). The tumor microenvironment (TME) of HRASmt demonstrated increased M1 macrophages in triple-negative BC (TNBC), HNSCC, squamous NSCLC, and UC; increased M2 macrophages in TNBC; and increased CD8+ T-cells in HNS
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 23 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 25 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
Abstract. Non-small cell lung cancer (NSCLC) is associated with a 5-year survival rate of only 28%, however, when caught at an early stage, it can be cured with surgery or stereotactic body radiotherapy (SBRT). Unfortunately, racial disparities may result in limited access to care for some patients. Liu et al. analyzed 64,999 cases of early-stage NSCLC treated between 2005 and 2017 from the Florida cancer registry and showed that Black patients had 36% lower odds of receiving curative-intent surgery compared to their White counterparts. This study highlights significant racial disparities in treatment patterns that must be addressed urgently.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 29 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Puerto Rican credit card debt hits $96M - 1 month(s) ago
The use of credit cards, as well as their issuance, has reached significantly high figures in the last two years, which has generated an excessive use that has resulted in an increase in Puerto Rican indebtedness. According to data from the Office of the Commissioner of Financial Institutions (OCIF), the increase at the end of 2022 and the third quarter of 2023, the credit card balance has already reached $96 million.
Source: www.theweeklyjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 1 month(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 1 month(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Toxic asbestos is now fully banned, a move that EPA calls ‘historic’ - 2 month(s) ago
Environmental Protection Agency bans chrysotile asbestos, the only form of the cancer-causing mineral that the U.S. still imports and uses in new products.
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments - 2 month(s) ago
The epidermal growth factor receptor (EGFR) is a transmembrane protein that influences the pathogenesis in a subset of non-small cell lung cancers (NSCLC) [1]. Activation of EGFR is achieved by somatic mutations that lead to a ligand-independent activation of EGFR and uncontrolled cell growth [2,3]. Over the past decades, multiple tyrosine kinase inhibitors (TKIs) have been developed to inhibit growth of EGFR-mutated NSCLC. These drugs affect the intrinsic mitochondrial apoptotic pathway and thereby induce cell death [4].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
Congratulations to our fellows @SamuelKareffMD @AsaadTrabolsi for leading this comprehensive review | The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors @GlopesMd @carisls https://t.co/adR85JnLJr